Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoTG: Docetaxel and Gemcitabine in Locally Advanced Breast Cancer
NCT01352494Phase 2Unknown
- Sponsor
- Korean Breast Cancer Study Group
- Start
- May 2011
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and gemcitabine in breast cancer, sponsored by Korean Breast Cancer Study Group. Primary endpoint: Complete Remission Rate at 2 years. Status: unknown.
02
Drugs
docetaxelgemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01352494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01352494.